Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
or

Biomarin Pharmaceuticals (BMRN)

Biomarin Pharmaceuticals (BMRN)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
60.26 -7.22 (-10.70%) 04/04/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 60.25 -0.01 (-0.02%) 16:56 ET
Quote Overview for Fri, Apr 4th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
59.99
Day High
66.49
Open 66.25
Previous Close 67.48 67.48
Volume 3,545,400 3,545,400
Avg Vol 1,560,865 1,560,865
Stochastic %K 6.77% 6.77%
Weighted Alpha -32.60 -32.60
5-Day Change -11.18 (-15.65%) -11.18 (-15.65%)
52-Week Range 59.99 - 94.85 59.99 - 94.85
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,873,632
  • Shares Outstanding, K 190,777
  • Annual Sales, $ 2,854 M
  • Annual Income, $ 426,860 K
  • EBIT $ 484 M
  • EBITDA $ 572 M
  • 60-Month Beta 0.30
  • Price/Sales 4.57
  • Price/Cash Flow 21.05
  • Price/Book 2.30

Options Overview Details

View History
  • Implied Volatility 49.86% ( +12.87%)
  • Historical Volatility 41.11%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 49.86% on 04/04/25
  • IV Low 22.57% on 04/26/24
  • Put/Call Vol Ratio 0.27
  • Today's Volume 1,326
  • Volume Avg (30-Day) 879
  • Put/Call OI Ratio 0.67
  • Today's Open Interest 35,862
  • Open Int (30-Day) 36,445

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.75
  • Number of Estimates 10
  • High Estimate 0.88
  • Low Estimate 0.49
  • Prior Year 0.49
  • Growth Rate Est. (year over year) +53.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
59.99 +0.45%
on 04/04/25
Period Open: 70.51
73.51 -18.02%
on 03/07/25
-10.25 (-14.54%)
since 03/04/25
3-Month
59.99 +0.45%
on 04/04/25
Period Open: 66.83
73.51 -18.02%
on 03/07/25
-6.57 (-9.83%)
since 01/03/25
52-Week
59.99 +0.45%
on 04/04/25
Period Open: 86.89
94.85 -36.47%
on 08/20/24
-26.63 (-30.65%)
since 04/04/24

Most Recent Stories

More News
Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks

Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks

SRPT : 54.43 (-7.13%)
BMRN : 60.26 (-10.70%)
VRTX : 474.62 (-1.94%)
MRNA : 25.11 (-2.41%)
AMGN : 294.39 (-4.99%)
5 Historically Cheap Growth Stocks to Buy With Confidence in the Wake of the Nasdaq Correction

Stock market downturns are traditionally the ideal time to go shopping for bargains.

PYPL : 58.37 (-5.41%)
COMP : 8.28 (-1.78%)
GOOGL : 145.60 (-3.40%)
GOOG : 147.74 (-3.20%)
$NASX : 15,587.79 (-5.82%)
TTD : 46.24 (-5.79%)
$SPX : 5,074.08 (-5.97%)
BMRN : 60.26 (-10.70%)
AMZN : 171.00 (-4.15%)
2 Reasons to Like BMRN (and 1 Not So Much)

2 Reasons to Like BMRN (and 1 Not So Much)

BMRN : 60.26 (-10.70%)
Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks

Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks

SRPT : 54.43 (-7.13%)
BMRN : 60.26 (-10.70%)
ABBV : 186.96 (-7.28%)
MRNA : 25.11 (-2.41%)
BIIB : 122.98 (-5.91%)
Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)

Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)

SRPT : 54.43 (-7.13%)
BMRN : 60.26 (-10.70%)
GILD : 107.25 (-4.57%)
MRNA : 25.11 (-2.41%)
AMGN : 294.39 (-4.99%)
Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks

Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks

BMRN : 60.26 (-10.70%)
VRTX : 474.62 (-1.94%)
MRNA : 25.11 (-2.41%)
UTHR : 292.46 (-4.85%)
BIIB : 122.98 (-5.91%)
A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack

A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack

MYGN : 8.13 (-3.33%)
VRTX : 474.62 (-1.94%)
BMRN : 60.26 (-10.70%)
GILD : 107.25 (-4.57%)
MRNA : 25.11 (-2.41%)
INCY Stock Down on Disappointing Skin Disease Study Data

Shares of Incyte INCY were down 8.62% on Monday after the announcement of data from two late-stage studies on an oral small-molecule JAK1 inhibitor, povorcitinib, for the treatment of hidradenitis suppurativa...

BMRN : 60.26 (-10.70%)
INCY : 60.58 (-3.01%)
GILD : 107.25 (-4.57%)
GSK : 36.53 (-6.36%)
1 Healthcare Stock to Target This Week and 2 to Turn Down

1 Healthcare Stock to Target This Week and 2 to Turn Down

PACB : 1.2300 (+3.36%)
VTRS : 7.62 (-6.62%)
BMRN : 60.26 (-10.70%)
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

MYGN : 8.13 (-3.33%)
BMRN : 60.26 (-10.70%)
GILD : 107.25 (-4.57%)
ABBV : 186.96 (-7.28%)
MRNA : 25.11 (-2.41%)
EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCC

Bristol Myers BMY announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients...

BMRN : 60.26 (-10.70%)
GILD : 107.25 (-4.57%)
BMY : 55.30 (-3.32%)
LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia Study

Eli Lilly LLY and partner Incyte INCY announced that a late-stage study evaluating oral baricitinib in adolescent patients (aged 12-18) with severe alopecia areata (AA) showed clinically meaningful improvements...

BMRN : 60.26 (-10.70%)
LLY : 738.21 (-6.45%)
INCY : 60.58 (-3.01%)
GILD : 107.25 (-4.57%)
Roche Gets FDA Approval for Acute Ischemic Stroke Drug for Adults

Roche’s RHHBY member company, Genentech, announced the FDA approval of TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke (AIS) in adults.As a...

BMRN : 60.26 (-10.70%)
GILD : 107.25 (-4.57%)
RHHBY : 37.6500 (-5.92%)
Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4

Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4

SRPT : 54.43 (-7.13%)
MYGN : 8.13 (-3.33%)
BMRN : 60.26 (-10.70%)
ABBV : 186.96 (-7.28%)
MRNA : 25.11 (-2.41%)
Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug

Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).The...

BMRN : 60.26 (-10.70%)
GILD : 107.25 (-4.57%)
REGN : 573.45 (-6.09%)
RHHBY : 37.6500 (-5.92%)
Novartis Gets CHMP Opinion for Label Expansion of Fabhalta

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency has adopted a positive opinion for the label expansion of Fabhalta ((iptacopan).Fabhalta...

BMRN : 60.26 (-10.70%)
NVS : 105.85 (-5.71%)
GILD : 107.25 (-4.57%)
Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect

Sarepta Therapeutics (SRPT) To Report Earnings Tomorrow: Here Is What To Expect

SRPT : 54.43 (-7.13%)
MYGN : 8.13 (-3.33%)
BMRN : 60.26 (-10.70%)
What To Expect From United Therapeutics’s (UTHR) Q4 Earnings

What To Expect From United Therapeutics’s (UTHR) Q4 Earnings

MYGN : 8.13 (-3.33%)
BMRN : 60.26 (-10.70%)
UTHR : 292.46 (-4.85%)
What To Expect From Myriad Genetics’s (MYGN) Q4 Earnings

What To Expect From Myriad Genetics’s (MYGN) Q4 Earnings

MYGN : 8.13 (-3.33%)
BMRN : 60.26 (-10.70%)
GILD : 107.25 (-4.57%)
Why BioMarin Pharmaceutical Stock Zoomed Almost 5% Higher Today

BioMarin Pharmaceutical (NASDAQ: BMRN) was a lively stock in the best way on Thursday following the release of its latest set of quarterly results. Enthusiastic investors traded the company's shares up...

BMRN : 60.26 (-10.70%)
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today

Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today

BMRN : 60.26 (-10.70%)
BioMarin: EPS Surges Past Expectations

BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results.

BMRN : 60.26 (-10.70%)
BioMarin: Q4 Earnings Snapshot

BioMarin: Q4 Earnings Snapshot

BMRN : 60.26 (-10.70%)
BioMarin Pharmaceutical (NASDAQ:BMRN) Reports Bullish Q4, Stock Soars

BioMarin Pharmaceutical (NASDAQ:BMRN) Reports Bullish Q4, Stock Soars

BMRN : 60.26 (-10.70%)
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings

What To Expect From BioMarin Pharmaceutical’s (BMRN) Q4 Earnings

BMRN : 60.26 (-10.70%)
GILD : 107.25 (-4.57%)
ABBV : 186.96 (-7.28%)
BMY Q4 Earnings and Sales Beat Estimates, Shares Down on 2025 Outlook

Bristol-Myers Squibb Company BMY reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.67, which beat the Zacks Consensus Estimate of $1.46.  In the year-ago quarter, BMY posted an adjusted...

ALNY : 235.74 (-10.08%)
BMRN : 60.26 (-10.70%)
PFE : 22.97 (-5.43%)
BMY : 55.30 (-3.32%)
Will Non-COVID Drugs Drive PFE's Top Line in Q4 Earnings?

Pfizer’s PFE non-COVID operational revenues improved in the first three quarters of 2024, driven by its key in-line products like Vyndaqel and Eliquis, new launches like Abrysvo and newly acquired products...

ALNY : 235.74 (-10.08%)
BMRN : 60.26 (-10.70%)
PFE : 22.97 (-5.43%)
BNTX : 88.05 (-4.30%)
Novartis Posts Q4 Earnings and Sales Beat, Shares Gain

Swiss pharma giant Novartis AG NVS reported better-than-expected results for the fourth quarter of 2024. Core earnings (excluding one-time charges) of $1.98 per share easily beat the Zacks Consensus Estimate...

ALNY : 235.74 (-10.08%)
BMRN : 60.26 (-10.70%)
NVS : 105.85 (-5.71%)
RHHBY : 37.6500 (-5.92%)
10 Magnificent Stocks That Can Make You Richer in 2025

A new year brings with it new opportunities to grow your wealth on Wall Street.

BABA : 116.54 (-9.89%)
COMP : 8.28 (-1.78%)
META : 504.73 (-5.06%)
FVRR : 22.20 (-5.29%)
S : 16.91 (-5.58%)
V : 313.13 (-7.74%)
BMRN : 60.26 (-10.70%)
PINS : 25.78 (-6.29%)
PFE : 22.97 (-5.43%)
O : 55.15 (-3.35%)
NEE : 66.91 (-7.25%)
Is Incyte Stock Outperforming the Dow?

Incyte has outperformed the Dow recently, and analysts remain moderately optimistic about the stock’s prospects.

BMRN : 60.26 (-10.70%)
INCY : 60.58 (-3.01%)
$DOWI : 38,314.86 (-5.50%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder),...

See More

Key Turning Points

3rd Resistance Point 71.00
2nd Resistance Point 68.75
1st Resistance Point 64.50
Last Price 60.26
1st Support Level 58.00
2nd Support Level 55.75
3rd Support Level 51.50

See More

52-Week High 94.85
Fibonacci 61.8% 81.53
Fibonacci 50% 77.42
Fibonacci 38.2% 73.31
Last Price 60.26
52-Week Low 59.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades